# Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

> **NCT02142504** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 454 (actual)

## Conditions studied

- Norovirus Prevention

## Interventions

- **BIOLOGICAL:** Norovirus Bivalent VLP Vaccine
- **DRUG:** Placebo (Saline)

## Key facts

- **NCT ID:** NCT02142504
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-15
- **Primary completion:** 2016-01-06
- **Final completion:** 2016-01-06
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2017-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142504, "Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02142504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*